선행항암화학요법을 시행한 유방암 환자에서 영상학적 액와부 병기의 정확성
Accuracy of Radiological Axillary Staging for Breast Cancer Patients with Neoadjuvant Chemotherapy
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Neoadjuvant chemotherapy (NACT) in breast cancer patients has the advantage of decreasing related morbidities by reducing the extent of axillary surgery. However, it remains a controversy with regards to the appropriate extent of axillary lymph node dissection after NACT. Therefore, this study aims to investigate the accuracy of breast ultrasonography (US) and breast magnetic resonance imaging (MRI) to assess the axillary nodal status after NACT. Methods: We reviewed pre- and post-NACT axillary imaging and clinicopathological data of patients who received NACT for primary breast cancer and underwent surgery. After NACT, accuracy of imaging modalities were evaluated through the comparison of pathologic lymph node (LN) status and imaging LN status. Results: Fifty seven patients completed NACT and underwent surgery. Breast US was found to have a sensitivity of 61.1%, specificity of 57.7%, negative predictive value (NPV) of 68.2%, and positive predictive value (PPV) of 50.0%. For breast MRI, sensitivity was 58.3%, specificity 75.8%, NPV 71.4%, and PPV 63.6%. For US combined with MRI, sensitivity was 66.7%, specificity 54.5%, NPV 69.2%, and PPV 51.6%. The accuracy of imaging modalities was 59.1% for US, 68.4% for MRI, and 59.6% for US combined with MRI. Conclusion: In breast cancer patients who received NACT, MRI showed a higher specificity, NPV, and PPV than US, although it had a lower sensitivity. However, due to the low accuracy, breast MRI alone is not sufficient to determine the extent of axillary surgery. Therefore, determining the extent of axillary surgery based on the results of intraoperative sentinel lymph node biopsy may be the right method for accurate staging.
Abstract
Purpose: Neoadjuvant chemotherapy (NACT) in breast cancer patients has the advantage of decreasing related morbidities by reducing the extent of axillary surgery. However, it remains a controversy with regards to the appropriate extent of axillary lymph node dissection after NACT. Therefore, this study aims to investigate the accuracy of breast ultrasonography (US) and breast magnetic resonance imaging (MRI) to assess the axillary nodal status after NACT. Methods: We reviewed pre- and post-NACT axillary imaging and clinicopathological data of patients who received NACT for primary breast cancer and underwent surgery. After NACT, accuracy of imaging modalities were evaluated through the comparison of pathologic lymph node (LN) status and imaging LN status. Results: Fifty seven patients completed NACT and underwent surgery. Breast US was found to have a sensitivity of 61.1%, specificity of 57.7%, negative predictive value (NPV) of 68.2%, and positive predictive value (PPV) of 50.0%. For breast MRI, sensitivity was 58.3%, specificity 75.8%, NPV 71.4%, and PPV 63.6%. For US combined with MRI, sensitivity was 66.7%, specificity 54.5%, NPV 69.2%, and PPV 51.6%. The accuracy of imaging modalities was 59.1% for US, 68.4% for MRI, and 59.6% for US combined with MRI. Conclusion: In breast cancer patients who received NACT, MRI showed a higher specificity, NPV, and PPV than US, although it had a lower sensitivity. However, due to the low accuracy, breast MRI alone is not sufficient to determine the extent of axillary surgery. Therefore, determining the extent of axillary surgery based on the results of intraoperative sentinel lymph node biopsy may be the right method for accurate staging.
참고문헌 (30)
- Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 68, pp.394~424 (2018)
- "2016 cancer registry statistics in Korea" (2019)[URL]
- Pilewskie M, "Axillary nodal management following neoadjuvant chemotherapy : a review", JAMA Oncol, 3, pp.549~555 (2017)
- Fisher B, "Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer : findings from national surgical adjuvant breast and bowel project B-18", J Clin Oncol, 15, pp.2483~2493 (1997)
- Bear HD, "The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide : preliminary results from national surgical adjuvant breast and bowel project protocol B-27", J Clin Oncol, 21, pp.4165~4174 (2003)
- Lyman GH, "Appropriate role for sentinel node biopsy after neoadjuvant chemotherapy in patients with early-stage breast cancer", J Clin Oncol, 33, pp.232~234 (2015)
- Fu JF, "Feasibility and accuracy of sentinel lymph node biopsy in clinically node-positive breast cancer after neoadjuvant chemotherapy : a meta-analysis", PLoS One, 9, pp.e105316~ (2014)
- Kang YJ, "Outcome following sentinel lymph node biopsy-guided decisions in breast cancer patients with conversion from positive to negative axillary lymph nodes after neoadjuvant chemotherapy", Breast Cancer Res Treat, 166, pp.473~480 (2017)
- Schijven MP, "Comparison of morbidity between axillary lymph node dissection and sentinel node biopsy", Eur J Surg Oncol, 29, pp.341~350 (2003)
- Ye BB, "Accuracy of axillary ultrasound after different neoadjuvant chemotherapy cycles in breast cancer patients", Oncotarget, 8, pp.36696~36706 (2017)
- Boughey JC, "Axillary ultrasound after neoadjuvant chemotherapy and its impact on sentinel lymph node surgery : results from the American college of surgeons oncology group Z1071 trial(alliance)", J Clin Oncol, 33, pp.3386~3393 (2015)
- Schwentner L, "Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy–results from the multi-center SENTINA trial", The Breast, 31, pp.202~207 (2017)
- American joint committee on cancer (AJCC), "AJCC cancer staging manual" (2017), Springer
- 이한용, "림프절 양성 유방암의 선행항암화학요법 후 잔여 액와부 림프절 전이의 예측 인자", Journal of Breast Disease, 4(2), pp.42~47 (2016), 한국유방암학회[DOI]
- Ashikaga T, "Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection", J Surg Oncol, 102, pp.111~118 (2010)
- Liu CQ, "Late morbidity associatedwithatumour-negative sentinel lymph node biopsy in primary breast cancer patients : a systematic review", Eur J Cancer, 45, pp.1560~1568 (2009)
- Ahmed RL, "Lymphedema and quality of life in breast cancer survivors : the Iowa women’s health study", J Clin Oncol, 26, pp.5689~5696 (2008)
- Arimappamagan A, "Complete axillary conversion after neoadjuvant chemotherapy in locally advanced breast cancer : a step towards conserving axilla", Indian J Cancer, 41, pp.13~17 (2004)
- Hieken TJ, "Imag-ing response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer", Ann Surg Oncol, 20, pp.3199~3204 (2013)
- Di Micco R, "Sentinel node biopsy after primary systemic therapy in node positive breast cancer patients : time trend, imaging staging power and nodal downstaging according to molecular subtype", Eur J Surg Oncol, 45, pp.969~975 (2019)
- Bhattacharyya M, "Using MRI to plan breast-conserving surgery following neoadjuvant chemotherapy for early breast cancer", Br J Cancer, 98, pp.289~293 (2008)
- Rieber A, "Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy", Eur Radiol, 12, pp.1711~1719 (2002)
- Martincich L, "Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging", Breast Cancer Res Treat, 83, pp.67~76 (2004)
- Yeh E, "Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer", Am J Roentgenol, 184, pp.868~877 (2005)
- Javid S, "Can breast MRI predict axillary lymph node metastasis in women undergoing neoadjuvant chemotherapy", Ann Surg Oncol, 17, pp.1841~1846 (2010)
- Steiman J, "Predictive value of axillary nodal imaging by magnetic resonance imaging based on breast cancer subtype after neoadjuvant chemotherapy", J Surg Res, 204, pp.237~241 (2016)
- Kim JY, "Tumour 18 F-FDG uptake on preoperative PET", CT may predict axillary lymph node metastasis in ER-positive, Eur Radiol, pp.2015, 25[DOI]
- fluoro-3’-deoxythymidine with positron emissiontomography in predicting breast cancer response to therapy, "Mol Imaging Biol", 2006, 36~42
- Boughey JC, "Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer : the ACOSOG Z1071(alliance)clinical trial", JAMA, 310, pp.1455~1461 (2013)
- Kuehn T, "Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy(SENTINA) : a prospective, multicentre cohort study", Lancet Oncol, 14, pp.609~618 (2013)